국소 췌장암의 액체 생검(ctDNA) 유도 치료: 신보조 CTX 대 선행 수술 (LIQUIPANC)
국소 췌장암의 액체 생검 유도 치료(LIQUIPANC): 선행 화학요법과 선행 수술의 계층화를 위한 정밀 의학 도구로서의 순환 종양 DNA(ctDNA)
This study evaluates the clinical prognostic impact (on DFS and OS) of liquid biopsy guided treatment vs. standard of care (physicians choice) in localized pancreatic cancer (CA 19-9 levels <500, no vessel contact and recommended by multidisciplinary tumor board). ctDNA positive patients are randomized to either receive neoadjvuant chemotherapy at current gold standard physicians choice vs. upfront surgery because of assumed high biological risk for early recurrence of ctDNA+. ctDNA- will receive upfront surgery in adherence to local guidelines.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
Pancreatic ductal adenocarcinoma (PDAC) is characterized by high recurrence rates and poor long-term survival, even following potentially curative surgical resection and modern multimodal treatment. Despite improvements in surgical techniques, perioperative management, and systemic chemotherapy, a substantial proportion of patients with anatomically resectable PDAC experience early disease recurrence, suggesting the presence of occult systemic disease that cannot be adequately identified by conventional staging methods.
Current treatment decisions are primarily based on radiological resectability, clinical performance status, and established biomarkers such as carbohydrate antigen 19-9 (CA19-9). However, these parameters provide limited information about individual tumor biology and the risk of early recurrence. Consequently, patients with apparently favorable anatomical characteristics may still harbor biologically aggressive disease.
Circulating tumor DNA (ctDNA) has emerged as a promising minimally invasive biomarker for assessing tumor biology, monitoring treatment response, and predicting oncological outcomes. In previous studies, the investigators demonstrated that an early decrease in ctDNA levels of at least 42% after two weeks of systemic chemotherapy could predict subsequent radiological treatment response with high sensitivity and specificity, substantially earlier than conventional imaging (Kirchweger et al., Frontiers in Oncology, 2022). Furthermore, pretherapeutic ctDNA positivity in patients with localized PDAC was associated with significantly shorter disease-free survival (3.3 vs. 18.1 months), despite the absence of radiological evidence of advanced or metastatic disease (Kirchweger et al., European Journal of Surgical Oncology, 2021).
These findings suggest that pretherapeutic ctDNA detection may identify patients at increased risk of early recurrence who could potentially benefit from neoadjuvant systemic treatment, even when conventional clinical and radiological criteria favor upfront surgery.
However, a universal neoadjuvant treatment approach for all patients with anatomically resectable PDAC remains controversial. Although neoadjuvant chemotherapy may provide early systemic disease control and reveal aggressive tumor biology, it also exposes patients to treatment-related toxicity, potential deterioration in quality of life, and the risk of losing the opportunity for surgical resection due to disease progression or treatment intolerance. Therefore, a more individualized treatment strategy incorporating biological risk assessment may help optimize treatment sequencing.
The LIQUIPANC study is a prospective, multicenter, randomized clinical trial investigating the prognostic and potential clinical utility of ctDNA-guided treatment strategies in patients with anatomically resectable PDAC.
Eligible patients have localized PDAC without radiological vessel involvement, CA19-9 levels below 500 U/mL, and a multidisciplinary tumor board recommendation for upfront surgical resection based on conventional staging.
Following informed consent, approximately 30 mL of peripheral blood is collected before the initiation of oncological treatment. Plasma-derived ctDNA is analyzed using droplet digital polymerase chain reaction (ddPCR), primarily targeting KRAS G12/G13 mutations, with additional KRAS Q61 testing if the initial analysis is negative.
Treatment allocation is determined as follows:
ctDNA-positive patients: Patients with detectable ctDNA are randomized to one of two treatment strategies:
Neoadjuvant treatment arm: Patients receive neoadjuvant chemotherapy according to current standards of care and the treating physician's choice, followed by surgical resection when clinically feasible and subsequent treatment according to local guidelines.
Standard-of-care arm: Patients undergo upfront surgical resection, followed by adjuvant chemotherapy and further treatment according to current local guidelines and the treating physician's choice.
ctDNA-negative patients: Patients without detectable ctDNA are not randomized and undergo upfront surgical resection in accordance with the multidisciplinary tumor board recommendation and current local standards of care, followed by adjuvant treatment as indicated.
The randomized comparison among ctDNA-positive patients aims to investigate whether neoadjuvant chemotherapy, compared with upfront surgery, improves oncological outcomes in patients with potentially unfavorable tumor biology.
The overall study population will additionally be evaluated to investigate the prognostic significance of baseline ctDNA status and its association with disease recurrence and survival.
The primary endpoint is disease-free survival (DFS). Overall survival (OS) and the prognostic value of ctDNA detection are evaluated as additional outcomes.
LIQUIPANC aims to provide prospective clinical evidence regarding the feasibility and potential value of incorporating liquid biopsy into treatment decision-making for anatomically resectable PDAC. Ultimately, the study seeks to support a more personalized approach to treatment sequencing by identifying patients who may benefit from neoadjuvant systemic therapy while avoiding potentially unnecessary treatment delays and toxicity in others.
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
Upper Austria
-
Linz, Upper Austria, 오스트리아, 4010
- Ordensklinikum Linz Barmherzige Schwestern
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Informed consent
- >18 years old
- localized pancreatic cancer to go for upfront surgery
Exclusion Criteria:
- synchronous secondary malignancy
- pregnancy
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: ctDNA+ _ctDNA guided
All patients enrolled in the study have anatomically resectable pancreatic ductal adenocarcinoma (PDAC), without radiological vessel involvement and with CA19-9 levels below 500 U/mL, and have been recommended for upfront surgical resection by a multidisciplinary tumor board. Patients with detectable pretherapeutic circulating tumor DNA (ctDNA) are considered at increased biological risk for early disease recurrence and are randomized 1:1 to either neoadjuvant chemotherapy or upfront surgery. Patients allocated to this experimental arm receive neoadjuvant chemotherapy according to current standards of care and the treating physician's choice, followed by surgical resection when clinically feasible and subsequent treatment according to local guidelines. |
All patients included into the study are recommended to go for upfront surgery (CT and CA19-9) by tumor board. If preoperative ctDNA is positive, the investigators assume high risk for early recurrence (because of systemic tumor burden) and apply neoadjuvant chemotherapy at physicians choice instead.
FOLFIRONOX: Folinic acid (also known as leucovorin), F - Fluorouracil (5-FU), IRIN - Irinotecan, OX - Oxaliplatin.
다른 이름들:
|
|
다른: Standard of care
Patients assigned to this arm undergo upfront surgical resection as recommended by the multidisciplinary tumor board, followed by adjuvant chemotherapy and subsequent treatment according to current standards of care and the treating physician's choice. This arm includes two prespecified patient subgroups: ctDNA-positive patients randomized to upfront surgery as part of the randomized comparison with neoadjuvant chemotherapy. ctDNA-negative patients assigned to upfront surgery without randomization, in accordance with standard treatment recommendations. The primary randomized treatment comparison is restricted to ctDNA-positive patients. The ctDNA-negative subgroup is evaluated separately for exploratory analyses of the prognostic significance of baseline ctDNA status and oncological outcomes. |
Standard of care as recommended by tumor board (not affected by study conditions).
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
DFS
기간: After 12 months
|
Disease free survival |
After 12 months
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
OS
기간: After 12 months
|
Overall survival |
After 12 months
|
|
ctDNA detection rate
기간: Preoperatively
|
Detection rate of ctDNA in peripheral blood using a cost-effective and clinical applicable small spectrum ddPCR analysis in order to enable immediate clinical implementation |
Preoperatively
|
공동 작업자 및 조사자
협력자
협력자
수사관
수사관
- 수석 연구원: Patrick Kirchweger, MD, PhD, Ordensklinikum Linz, Department of Surgery
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (실제)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- 1199/2023
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .